Sponsors (7)
The bill shifts the U.S. patent system toward stronger, more court-centered property rights and steadier USPTO funding—benefiting patent owners and investors—while reducing administrative review, public transparency, and challenger access, which raises litigation costs and the likelihood that weak patents will persist, with potential harms to competition, consumers, and international patent strategies.
Small inventors, patent owners, and startups will get stronger, more enforceable patent rights (presumption of validity, ability to obtain injunctions, and limits on administrative revocations), making it easier to defend and monetize patents in court.
Tech and biotech companies, researchers, and investors gain greater incentives to invest in R&D and commercialization because stronger patent protections and preserved patent terms increase the expected returns on innovation.
Inventors and small businesses can keep pending applications confidential until issuance and (under restored pre‑AIA rules) have a U.S. one‑year grace period for public disclosure, giving them more control over when and how to commercialize new inventions.
Competitors, developers, and the public will have fewer, harder-to-use avenues to challenge weak or low‑quality patents because administrative reviews (IPR/PGR) would be curtailed, validity presumptions strengthened, and ex parte review left as the main PTO tool, increasing the risk that invalid patents persist.
Accused infringers, independent developers, and smaller firms will face higher litigation costs and longer disputes as more patent validity contests shift from faster, cheaper PTO proceedings to federal courts.
Consumers, patients, and downstream businesses could pay higher prices and face reduced access to products and diagnostics because extended effective patent exclusivity and broader eligibility (especially for diagnostics/biotech) can delay competition and generics.
Based on analysis of 24 sections of legislative text.
Overhauls U.S. patent law: reverses key AIA reforms, strengthens patent validity and injunctions, abolishes PTAB, limits publication of applications, broadens eligibility, and creates a USPTO fee revolving fund.
Introduced October 24, 2025 by Thomas Massie · Last progress October 24, 2025
Overhauls major parts of the U.S. patent system by reversing several America Invents Act (AIA) reforms, strengthening patent holders’ rights in court, limiting administrative patent challenges, changing what patent applications are made public, broadening what is patent-eligible, and creating a permanent USPTO fee fund. The changes boost presumptions of validity and make injunctions easier to get, restore a first-to-invent priority system and the older one‑year grace period, abolish key post‑grant administrative review procedures, and shift more patent disputes to the courts. The bill would affect inventors, universities, tech firms, small businesses, and the courts by increasing the legal value of issued patents while also likely increasing litigation costs, changing how patents are examined and funded, and reducing routine public disclosure of pending patent applications.